Anti-tumor effect of the complex of acriflavine and guanosine(AG60) = Acriflavine과 Guanosine 복합체(AG60)의 항암효과

Cited 0 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorEun-Kyung Hong-
dc.contributor.authorHwan Mook Kim-
dc.contributor.authorKyung-Yung Lee-
dc.contributor.authorYoung-Shin Chung-
dc.contributor.authorBo-Im Yoo-
dc.contributor.authorSang Geon Kim-
dc.contributor.authorE-Tay Ahn-
dc.contributor.authorYoung-Bok Han-
dc.date.accessioned2017-04-19T08:54:52Z-
dc.date.available2017-04-19T08:54:52Z-
dc.date.issued1997-
dc.identifier.issn0496-6872-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/4218-
dc.description.abstractPURPOSE: The anti-tumor effect of the complex of acriflavine and guanosine (AG60) was investigated. MATERIALS AND METHODS: In vitro cytotoxicity of AG60 was measured using SRB assay, and in vivo antitumor activity of AG60 was examined in CDF1 mice intraperitoneally inoculated with the P388 leukemic cells and in ICR mice inguinally implanted with S-180 cells. Tumor size and mean survival time were determined. RESULTS: AG60 and acriflavine showed strong anti-tumor effect in vitro on lung cancer (A549), renal cancer (UO-31) and colon cancer (COLO205) cells. However, AG60 did not show the cytotoxicity against normal cell line, 3T3. The range of the IC50 of AG60 to the various tumor cell lines was 0.09 microgram/ml through 1.94 microgram/ml. The treatment of ascitic tumor bearing CDF1 mice with AG60 resulted in over 160% increases in the mean survival time. The most effective dose of AG60 was 30 mg/kg body weight in tumor implanted mice. In solid tumor bearing ICR mice tumor growth and progression were suppressed in response to the different doses at 30 days; 69.8% suppression of tumor size in response to acriflavine, 16.0% to guanosine, 87.7% to AG60 and 78.5% to doxorubicin. In addition, 35% increases were observed in the means survival time of AG60 treated group compared with control group. CONCLUSION: The prominant anti-tumor effects of AG60 shown in this report would represent the possibility of the clinical trials.-
dc.publisherKorea Soc-Assoc-Inst-
dc.titleAnti-tumor effect of the complex of acriflavine and guanosine(AG60) = Acriflavine과 Guanosine 복합체(AG60)의 항암효과-
dc.title.alternativeAnti-tumor effect of the complex of acriflavine and guanosine(AG60)-
dc.typeArticle-
dc.citation.titleJournal of Korean Cancer Association-
dc.citation.number1-
dc.citation.endPage37-
dc.citation.startPage29-
dc.citation.volume29-
dc.contributor.affiliatedAuthorEun-Kyung Hong-
dc.contributor.affiliatedAuthorHwan Mook Kim-
dc.contributor.alternativeName홍은경-
dc.contributor.alternativeName김환묵-
dc.contributor.alternativeName이경영-
dc.contributor.alternativeName정영신-
dc.contributor.alternativeName유보림-
dc.contributor.alternativeName김상건-
dc.contributor.alternativeName안의태-
dc.contributor.alternativeName한영복-
dc.identifier.bibliographicCitationJournal of Korean Cancer Association, vol. 29, no. 1, pp. 29-37-
dc.subject.keywordAcriflavine-
dc.subject.keywordGuanosine-
dc.subject.keywordCytotoxicity-
dc.subject.keywordTumor growth inhibition-
dc.subject.localAcriflavine-
dc.subject.localGuanosine-
dc.subject.localCytotoxicity-
dc.subject.localcytotoxicity-
dc.subject.localTumor growth inhibition-
dc.description.journalClassN-
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.